Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

BMC Cancer

Ziliang Yang¹  Wei Peng¹  Minshan Chen¹  Jie Mei¹  Wenping Lin¹  Jinbin Chen¹  Yaojun Zhang¹  Li Xu¹  Xuqi Sun² 

[1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 510060, Guangzhou, China;Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, 510060, Guangzhou, China;Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 510060, Guangzhou, China;Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, 510060, Guangzhou, China;Zhongshan School of Medicine, Sun Yat-Sen University, 510060, Guangzhou, China;

关键词: Hepatocellular carcinoma;    AFP;    PIVKA-II;    Immunotherapy;    Survival;   

DOI  :  10.1186/s12885-021-08428-w

来源: Springer

【 摘 要 】

BackgroundFew biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy.MethodsA total of 235 HCC patients treated with PD-1 blockade were enrolled. Serum AFP and PIVKA-II levels were collected before and after treatments. The patients were divided into groups based on the reduction in AFP and PIVKA-II: AFP reduction ≤50% vs AFP reduction > 50% and PIVKA-II reduction ≤50% vs PIVKA-II reduction > 50%. The primary endpoints included objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Binary logistic regression analyses were used to explore the related factors of ORR. A Cox proportional hazards model was employed to identify the potential prognostic factors of PFS and OS.ResultsAmong all the patients, 34.9% (82/235) achieved a complete or partial response. There was a positive correlation between AFP reduction > 50% or PIVKA-II reduction> 50% and the ORR of PD-1 blockade (P < 0.001 and = 0.003). PFS was significantly improved in patients with AFP reduction > 50% and PIVKA-II reduction > 50% (p < 0.001 and = 0.021). In addition, AFP reduction > 50% and PIVKA-II reduction> 50% were positively correlated with longer OS (p = 0.003 and 0.006).ConclusionEarly reductions in AFP and PIVKA-II can be predictors of the efficacy of PD-1 blockade in HCC patients.

【 授权许可】

CC BY